Company: BLCO
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0001140361-25-013244
Chunk: 37

Company: Bausch & Lomb Corp
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 37
---
iatris in order to ensure the peer companies continue to reflect a robust group that includes a sufficient representation of companies in the eye care industry; no other peers were added or removed as a result of this review. Based on these criteria, the following is the list of peers selected for 2024:

| Agilent Technologies, Inc. (A)   
 Alcon Inc. (ALC)                 
 Align Technology, Inc. (ALGN)    
 The Cooper Companies, Inc. (COO) 
 Dentsply Sirona Inc. (XRAY)      |     | DexCom, Inc. (DXCM)                   
 Edwards Lifesciences Corporation (EW) 
 Hologic, Inc. (HOLX)                  
 Jazz Pharmaceuticals plc (JAZZ)       
 Organon & Co. (OGN)                   |     | Perrigo Company plc (PRGO)         
 ResMed Inc. (RMD)                  
 Teleflex Incorporated (TFX)        
 Viatris (VTRS)                     
 Zimmer Biomet Holdings, Inc. (ZBH) |

We use data from this peer group to benchmark pay levels, as well as pay practices. In addition to proxy data for the above companies, our Talent and Compensation Committee also utilizes Willis Towers Watson’s Pharmaceuticals and Health Sciences Survey to supplement this data both in terms of pay levels and pay practices. Our Talent and Compensation Committee references the median of the market data for total compensation opportunity as a guide when making decisions. Market data is one element that our Talent and Compensation Committee uses to make pay decisions. Multiple factors are considered in determining total compensation opportunity, including our compensation philosophy, the executive’s role and responsibility, the executive’s past performance, internal equity, and expected contributions and experience in the role. Shareholder Engagement At our 2024 Annual Meeting of Shareholders, we held a “say-on-pay” non-binding advisory vote with respect to the compensation of our NEOs. Approximately 95% of shareholders voted in favor of our executive compensation program. These “say-on-pay” results demonstrate strong support from all shareholders, including our largest shareholder, BHC, for our current executive compensation program and philosophy. Our Talent and Compensation Committee is committed to ongoing direct engagement with our shareholders through investor meetings as well as conferences and other forums, in order to solicit feedback on our compensation philosophy and underlying programs, and consider the feedback received from shareholders regarding our executive compensation program. Components of Executive Compensation The components of executive compensation for our NEOs, as described in more detail below, include:

| + |